NAS:GHDX (USA) Also trade in: Germany

Genomic Health Inc

$ 54.07 0.88 (1.65%)
Volume: 754,652 Avg Vol (1m): 549,797
Market Cap $: 2.00 Bil Enterprise Value $: 1.80 Bil
P/E (TTM): 48.28 P/B: 7.30
Earnings Power Value 12.3
Net Current Asset Value 4.53
Tangible Book 7.43
Projected FCF 7.11
Median P/S Value 39.66
Graham Number 13.68
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
98.47% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
GHDX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 4.9, Med: 10000, Max: 10000
Current: 10000
4.9
10000
Equity-to-Asset 0.73
Equity-to-Asset ranked higher than
81.17% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
GHDX: 0.73
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -3.56, Med: 0.8, Max: 0.89
Current: 0.73
-3.56
0.89
Interest Coverage No Debt
Interest Coverage ranked higher than
98.16% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
GHDX: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 125.61, Med: 10000, Max: 10000
Current: 10000
125.61
10000
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 13.15
DISTRESS
GREY
SAFE
Beneish M-Score -1.26
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 55.66%
WACC 8.83%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 9.71
Operating Margin ranked lower than
51.65% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
GHDX: 9.71
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -9.76, Med: -2.03, Max: 9.71
Current: 9.71
-9.76
9.71
Net Margin % 10.35
Net Margin ranked higher than
52.28% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
GHDX: 10.35
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -11.59, Med: -2.69, Max: 10.35
Current: 10.35
-11.59
10.35
ROE % 17.26
ROE ranked higher than
54.13% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
GHDX: 17.26
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -23.37, Med: -5.82, Max: 17.26
Current: 17.26
-23.37
17.26
ROA % 13.79
ROA ranked higher than
53.05% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
GHDX: 13.79
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -17.98, Med: -4.5, Max: 13.79
Current: 13.79
-17.98
13.79
ROC (Joel Greenblatt) % 69.13
ROC (Joel Greenblatt) ranked lower than
50.19% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
GHDX: 69.13
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -76.38, Med: -17.93, Max: 105.94
Current: 69.13
-76.38
105.94
3-Year Total Revenue Growth Rate 11.10
3-Year Revenue Growth Rate ranked higher than
50.00% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
GHDX: 5.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 11.8, Max: 136.5
Current: 5.7
0
136.5

» GHDX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GHDX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare NAS:QDEL NAS:MYGN BSP:DASA3 NAS:MEDP NAS:NEO SHSE:603882 NYSE:NVTA NAS:BEAT SZSE:300463 SZSE:300244 NAS:NEOG SZSE:300482 BSP:FLRY3 TSE:4544 SZSE:300406 OSTO:SECT B NAS:VREX NSE:LALPATHLAB NAS:NTRA TSE:4694
Traded in other countries G7H.Germany
Address 301 Penobscot Drive, Redwood City, CA, USA, 94063
Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 48.28
PE Ratio ranked lower than
100.00% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
GHDX: 48.28
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 47.38, Med: 125.48, Max: 901.75
Current: 48.28
47.38
901.75
Forward PE Ratio 37.88
Forward P/E ranked lower than
100.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
GHDX: 37.88
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 48.28
PE without NRI ranked lower than
100.00% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
GHDX: 48.28
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 47.38, Med: 125.48, Max: 901.75
Current: 48.28
47.38
901.75
Price-to-Owner-Earnings 73.78
Price-to-Owner-Earnings ranked lower than
100.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
GHDX: 73.78
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 66.11, Med: 138.42, Max: 12416.67
Current: 73.78
66.11
12416.67
PB Ratio 7.30
PB Ratio ranked lower than
66.12% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
GHDX: 7.3
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4.81, Med: 6.92, Max: 12.06
Current: 7.3
4.81
12.06
PS Ratio 5.05
PS Ratio ranked higher than
53.91% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
GHDX: 5.05
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.17, Med: 3.69, Max: 7.88
Current: 5.05
2.17
7.88
Price-to-Free-Cash-Flow 36.80
Price-to-Free-Cash-Flow ranked lower than
96.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
GHDX: 36.8
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 34.35, Med: 58.93, Max: 14545
Current: 36.8
34.35
14545
Price-to-Operating-Cash-Flow 30.87
Price-to-Operating-Cash-Flow ranked lower than
80.41% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
GHDX: 30.87
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 27.44, Med: 44.51, Max: 1560.53
Current: 30.87
27.44
1560.53
EV-to-EBIT 45.17
EV-to-EBIT ranked lower than
100.00% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
GHDX: 45.17
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -291.9, Med: -32, Max: 3316.9
Current: 45.17
-291.9
3316.9
EV-to-EBITDA 34.09
EV-to-EBITDA ranked lower than
100.00% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
GHDX: 34.09
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -2637.8, Med: 36.7, Max: 1417.8
Current: 34.09
-2637.8
1417.8
EV-to-Revenue 4.41
EV-to-Revenue ranked higher than
64.46% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
GHDX: 4.41
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.8, Med: 3.3, Max: 7.8
Current: 4.41
1.8
7.8
Current Ratio 5.67
Current Ratio ranked higher than
66.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
GHDX: 5.67
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.26, Med: 4.54, Max: 155.33
Current: 5.67
3.26
155.33
Quick Ratio 5.67
Quick Ratio ranked higher than
68.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
GHDX: 5.67
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.26, Med: 4.54, Max: 155.33
Current: 5.67
3.26
155.33
Days Sales Outstanding 52.71
Days Sales Outstanding ranked higher than
86.27% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
GHDX: 52.71
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 27.15, Med: 38.25, Max: 52.71
Current: 52.71
27.15
52.71
Days Payable 54.17
Days Payable ranked lower than
98.93% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
GHDX: 54.17
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 1.04, Med: 46.44, Max: 75.79
Current: 54.17
1.04
75.79

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.60
3-Year Share Buyback Rate ranked higher than
70.00% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
GHDX: -4.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -197.9, Med: -3.2, Max: -1
Current: -4.6
-197.9
-1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 7.28
Price-to-Tangible-Book ranked higher than
51.21% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
GHDX: 7.28
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.3, Med: 6.85, Max: 11.76
Current: 7.28
3.3
11.76
Price-to-Projected-FCF 7.60
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
88.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
GHDX: 7.6
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 4.19, Med: 8.48, Max: 38.47
Current: 7.6
4.19
38.47
Price-to-Median-PS-Value 1.36
Price-to-Median-PS-Value ranked higher than
61.14% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
GHDX: 1.36
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.62, Med: 1.03, Max: 4.29
Current: 1.36
0.62
4.29
Price-to-Graham-Number 3.95
Price-to-Graham-Number ranked lower than
100.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
GHDX: 3.95
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 3.88, Med: 6.4, Max: 15.7
Current: 3.95
3.88
15.7
Earnings Yield (Joel Greenblatt) % 2.24
Earnings Yield (Greenblatt) ranked higher than
52.83% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
GHDX: 2.24
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5.4, Med: -1.1, Max: 2.28
Current: 2.24
-5.4
2.28

More Statistics

Revenue (TTM) (Mil) $ 410.26
EPS (TTM) $ 1.12
Beta 1.07
Volatility % 48.19
52-Week Range $ 36.94 - 92.18
Shares Outstanding (Mil) 37.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N